IDEXX Laboratories, Inc. (NASDAQ:IDXX) CEO Jonathan W. Ayers sold 2,160 shares of the business’s stock in a transaction that occurred on Thursday, January 11th. The stock was sold at an average price of $167.03, for a total transaction of $360,784.80. Following the transaction, the chief executive officer now owns 1,077,112 shares of the company’s stock, valued at approximately $179,910,017.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Shares of IDEXX Laboratories, Inc. (IDXX) traded up $5.37 during trading on Thursday, reaching $171.51. 512,720 shares of the company’s stock were exchanged, compared to its average volume of 464,260. The company has a debt-to-equity ratio of -12.48, a current ratio of 0.95 and a quick ratio of 0.77. IDEXX Laboratories, Inc. has a twelve month low of $116.54 and a twelve month high of $173.01. The firm has a market cap of $14,960.00, a price-to-earnings ratio of 55.69, a price-to-earnings-growth ratio of 2.29 and a beta of 0.42.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, October 31st. The company reported $0.79 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.05. IDEXX Laboratories had a net margin of 14.55% and a negative return on equity of 336.64%. The business had revenue of $492.00 million for the quarter, compared to analyst estimates of $492.94 million. During the same quarter in the prior year, the business posted $0.62 EPS. IDEXX Laboratories’s revenue for the quarter was up 9.7% compared to the same quarter last year. equities research analysts anticipate that IDEXX Laboratories, Inc. will post 3.24 EPS for the current fiscal year.

Several research analysts recently commented on the stock. BidaskClub upgraded shares of IDEXX Laboratories from a “sell” rating to a “hold” rating in a research note on Friday, January 5th. Aegis reiterated a “sell” rating on shares of IDEXX Laboratories in a research note on Friday, December 8th. Zacks Investment Research upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 price objective for the company in a research note on Tuesday, October 24th. Stifel Nicolaus reiterated a “buy” rating and set a $185.00 price objective on shares of IDEXX Laboratories in a research note on Tuesday, October 24th. Finally, Canaccord Genuity reiterated a “buy” rating and set a $180.00 price objective on shares of IDEXX Laboratories in a research note on Friday, October 6th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $173.67.

Several large investors have recently added to or reduced their stakes in IDXX. Schroder Investment Management Group increased its stake in shares of IDEXX Laboratories by 281.0% in the second quarter. Schroder Investment Management Group now owns 66,856 shares of the company’s stock worth $10,733,000 after acquiring an additional 49,310 shares during the period. Commonwealth Bank of Australia increased its stake in shares of IDEXX Laboratories by 19.3% in the second quarter. Commonwealth Bank of Australia now owns 1,576 shares of the company’s stock worth $252,000 after acquiring an additional 255 shares during the period. Franklin Resources Inc. increased its stake in shares of IDEXX Laboratories by 0.4% in the second quarter. Franklin Resources Inc. now owns 402,704 shares of the company’s stock worth $65,005,000 after acquiring an additional 1,721 shares during the period. Martingale Asset Management L P acquired a new stake in shares of IDEXX Laboratories in the second quarter worth $324,000. Finally, Dai Ichi Life Insurance Company Ltd increased its stake in shares of IDEXX Laboratories by 180.2% in the second quarter. Dai Ichi Life Insurance Company Ltd now owns 18,971 shares of the company’s stock worth $3,062,000 after acquiring an additional 12,201 shares during the period. Hedge funds and other institutional investors own 86.61% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “IDEXX Laboratories, Inc. (IDXX) CEO Jonathan W. Ayers Sells 2,160 Shares” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2018/01/11/idexx-laboratories-inc-idxx-ceo-jonathan-w-ayers-sells-2160-shares.html.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Insider Buying and Selling by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.